Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It Sure was!!!! have a nice day
"Well good for you"
This time last year in the .40's
Christmas approaching.. I'm on board
Oil prises moving up this am, going to be a big day
congrates on who bought below 10!
holding well, no one wants to let go just in case.
I'd have to agree here. $2.50 to 3 IMO
slightly smaller revenue, but larger OS and Float, but ultimately puts BBEPQ back above 2 per share. hopefully the outcome will favor share holder value for once,
https://ca.finance.yahoo.com/q/ks?s=UPLMQ
https://ca.finance.yahoo.com/q/ks?s=BBEPQ
Where's the cheering section today?! UPLMQ did similar moves, it will go higher
bitcoin is dead, save your money here.
please do then Js "enough for me to say see you"
go play another stock
Agreed, this will be 10 cents first quarter next year
If I was EVTI. I'd be asking for my money back from Aim High Profit losers.
Yes, low oil prices, tax loss season etc. looking more forward to Q1 actually
they should have picked a better newspaper
GL , read carefully
they have and
"AmHighProfits.com expects to be compensated $10,000 USD by ADT Consulting in an effort to build industry and investor awareness for Tamino Minerals Inc. (ticker symbol: TINO)."
anything Aim High Profits promotes...short it! always works.
B list promoters
Bullish kicker..... Looking great here
all flights will be cancelled , this will drop
looking real interesting here.
nice work!
takes time to build an oil company. slow steady as she goes, this time next year, we just may have sailed!
GL
VNDM diluting this pig badly... swim carefully here.
nothing happening here until 2015. most likely have time to buy lower.
"To advance the development, PositiveID has engaged Infinite Vision, an engineering development and contract manufacturing firm specializing in medical and biotech products.
By teaming with Infinite Vision, PositiveID expects to be able to demonstrate a bench top prototype of the Firefly cartridge in the first half of 2015, and targets having a full handheld prototype by the end of 2015. In line with this schedule, PositiveID expects to supply testing data in 2015 that demonstrates the speed, sensitivity, and specificity of the Firefly system, and ultimately positions the Company for government and commercial opportunities."
the chart is turning, perhaps private placement funds soon....
TXHE
highly plausible, watching the chart closely
GL
too bad this didn't RM into Alibaba . That said, not hard to do business with them now!!
GL
thanks govprs ...I will have a look see
bull bear fight.....hoping for a squeeze soon!
some big trades going through.....something coming up!!!
Go Texhoma!!!!!!!!
wouldn't the investigation be bad?
why the surge.... #don't-get-it
News
Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod
Conference Call Today at 11:00 AM ET
share with linkedin
tweet
share with facebook
BUFFALO, NY--(Marketwired - Sep 3, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the minutes from its meeting with the U.S. Food and Drug Administration (FDA) in July confirmed that the Company's existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.
Yakov Kogan, Ph.D, MBA, Chief Executive Officer of Cleveland BioLabs, stated, "The outcome of our FDA meeting is very positive and we are pleased with the agreements we have reached with the agency. Our achievement of animal-to-human dose conversion and the FDA's acknowledgement of the conceptual soundness of our dose-conversion methods are significant milestones in entolimod's development under the FDA's Animal Rule."
"We are starting preparations for a pre-EUA application which, if authorized, would allow for entolimod's use in the event of a radiological or nuclear emergency. In parallel, we are continuing our discussions with various U.S. government agencies regarding potential co-sponsorship and support for a pre-EUA submission for entolimod, as well as ongoing funding for the remaining development steps required for full licensure. We believe that entolimod has enormous potential to save lives as part of the nation's defense against a radiological or nuclear disaster and are dedicated to moving its development forward."
A pivotal efficacy study conducted in 179 non-human primates (NHPs) demonstrated that a single intramuscular injection of entolimod given 25 hours after high-dose, whole-body irradiation increased survival from 27.5% in control animals to 75% in treated animals -- a highly statistically significant, nearly three-fold improvement. These results were obtained without the use of any antibiotics or supportive care. A second, pivotal dose-conversion study conducted in 160 NHPs established the dose-dependent effect of entolimod on biomarkers for efficacy in non-irradiated NHPs.
Clinical studies of entolimod in 150 healthy human subjects have demonstrated the safety profile of entolimod and established the dose-dependent effect of entolimod on efficacy biomarkers in humans. In addition, entolimod has been administered to 25 patients with advanced cancer in an ongoing Phase 1 study.
The FDA has granted Fast Track status to entolimod and Orphan Drug status for prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.
Conference Call Information
Cleveland BioLabs management will host a conference call at 11:00 a.m. ET today to discuss these developments and address questions. Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the Investors page of the Cleveland BioLabs web site at www.cbiolabs.com. A replay of the call will be available starting on September 3, 2014, at 2:00 p.m. ET through September 17, 2014, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13589652. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs web site at www.cbiolabs.com.
About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are entolimod, which is being developed for a biodefense indication and as a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.
This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "intend," "would allow," "potential" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the safety of entolimod, the ability of entolimod to increase survival rates after irradiation, our ability to successfully develop and commercialize entolimod; the conduct and results of our various clinical trials; our ability to obtain pre-EUA approval from the U.S. Food and Drug Administration for entolimod and subsequent full licensure; our ability to find partnerships and sources of funding to a pre-EUA submission and full licensure; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include, among others, the Company's inability to demonstrate the safety and efficacy of entolimod as a radiation countermeasure, the Company's failure to successfully and timely develop entolimod and existing and new products; the Company's inability to obtain EUA approval for entolimod and subsequent full licensure; the Company's collaborative relationships, including the Company's inability to obtain co-sponsorship and financial support for the development of entolimod from U.S. government agencies, and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's ability to comply with its obligations under license agreements; the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.
did not get a chance to listen to the presentation..... look promising! chart does
Must be good news with the FDA! last year this time was trading at 1.50
Notification That Annual Report Will Be Submitted Late (nt 10-k)
WTF would they be late..... oh right, they forgot it was due.
these clowns are pathetic
sell the shell you &^%$# losers,
was there a mention of a RS coming!?
link if someone can please
stop losses triggered, bounce time coming
Yup wait and win..
from 8 k
"We are also in high level negotiations with Saudi Arabia and Turkey with the expectation of orders any day.
Additionally, we are receiving numerous worldwide inquiries regarding our wifi wearable cameras worn by police and military personnel, and are negotiating with a company in New York to sell Lamperd products, exclusively in the United States plus Central and South America"
nite on the buy
News is pass tense, I suspect more to follow like closing 5 mill private placement = kaboom
Numerous scenarios can arise from the 5 million
• Purchase land based assets and Drill new wells!
• Buy property with existing wells for cash flow, and drill more on the same land, or stimulate the existing wells for increased production (I.E acid or frack jobs)
• Partner up with a bigger player for a percentage on a new drilling program (this scenario bodes well and eliminates a lot of risk). Typically how all Starter oil companies come to fruition.
which ever case above, I hope they do the right deal for shareholder value. Given the float is still low, only a couple of hundred BOE/Day can push this over 1 dollar in a blink.
GLTA
interesting, thanks
where's the link?